Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

PaperCitations, authors & open-access status

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 12 citations, 2025 year and green oa status.

12
Citations
2025
Year
green
OA Status

Related on ScholarIQ

Masaomi Nangaku
Author
Hiddo J.L. Heerspink
Author
Julio Rosenstock
Author
Muthiah Vaduganathan
Author
Peter Rossing
Author
Diabetes Care
Journal
470M+ articles · free account